Introduction
Molecular profiling has transformed treatment strategy in non-small cell lung cancer with actionable genomic alterations.
Biomarker Testing
Comprehensive NGS panels and PD-L1 evaluation are now standard for advanced NSCLC workup at AVMC.
Targeted Agents in Current Use
Osimertinib, alectinib, lorlatinib, and KRAS-targeted therapies have shifted treatment outcomes in selected cohorts.
Resistance Mechanisms and Management
Serial liquid biopsy at progression helps map resistance pathways and supports informed subsequent therapy decisions.
Conclusion
Targeted therapy has materially improved outcomes where genomic profiling is available and integrated into routine decisions.